Literature DB >> 6307331

The effect of enalapril on serum prolactin.

W R McNabb, B A Brooks, F Noormohamed, A F Lant, H J Gomez, V J Cirillo, M Hichens, J A Bolognese.   

Abstract

Twelve healthy male volunteers received single daily oral doses of enalapril (EN) 10 mg for 8 consecutive days. Serum samples for prolactin (PRL) assay were taken on day 0 (baseline) at 12.00 h and 16.00 h, and on days 1 and 8 at 08.00 h (pre-drug), 12.00 h and 16.00 h. The 08.00 h values on day 1 served as the pre-drug baseline. There were no significant changes from baseline in serum PRL levels on days 1 and 8. All mean serum PRL levels on day 8 were significantly (P less than 0.01) lower than the upper limit of the normal range (2-15 ng/ml) found for healthy males in this laboratory. It is concluded that therapeutic doses of EN (10 mg/day, p.o.) for 8 consecutive days do not raise mean serum PRL levels above the normal range in healthy male volunteers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307331      PMCID: PMC1427928          DOI: 10.1111/j.1365-2125.1983.tb01562.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Prolactin.

Authors:  A G Frantz
Journal:  N Engl J Med       Date:  1978-01-26       Impact factor: 91.245

2.  Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa.

Authors:  R W Turkington
Journal:  Arch Intern Med       Date:  1972-09

3.  Verapamil-induced hyperprolactinemia and galactorrhea.

Authors:  L E Gluskin; B Strasberg; J H Shah
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

4.  Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.

Authors:  J Biollaz; M Burnier; G A Turini; D B Brunner; M Porchet; H J Gomez; K H Jones; F Ferber; W B Abrams; H Gavras; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

5.  Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.

Authors:  C S Sweet; D M Gross; P T Arbegast; S L Gaul; P M Britt; C T Ludden; D Weitz; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

Review 6.  Serum levels of anticonvulsant drugs. Interpretation and clinical value.

Authors:  E H Reynolds
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

7.  Drugs and impaired male sexual function.

Authors:  J D Horowitz; A J Goble
Journal:  Drugs       Date:  1979-09       Impact factor: 9.546

8.  Cimetidine, an H2-antihistamine, stimulates prolactin secretion in man.

Authors:  H E Carlson; A F Ippoliti
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

9.  Hyperprolactinaemia and impotence.

Authors:  S Franks; H S Jacobs; N Martin; J D Nabarro
Journal:  Clin Endocrinol (Oxf)       Date:  1978-04       Impact factor: 3.478

10.  Short- and long-term fluctuations in plasma prolactin concentration in normal subjects.

Authors:  H Djursing; C Hagen; J Møller; C Christiansen
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05
View more
  3 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

Review 2.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 3.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.